Biosynex S.A. Acquires ProciseDx Inc.
June 13, 2023
French diagnostics company Biosynex S.A. has acquired ProciseDx Inc., a U.S.-based point-of-care in vitro diagnostics company. The acquisition will help Biosynex commercialize ProciseDx's therapeutic drug monitoring (TDM) tests for infliximab and adalimumab in the United States and accelerate point-of-care biologic drug monitoring.
- Buyers
- Biosynex S.A.
- Targets
- ProciseDx Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eurobio Scientific Acquires CareDx Lab Products Division
April 16, 2026
Healthcare Services
Eurobio Scientific entered into a definitive agreement to acquire CareDx’s Lab Products transplant lab products division for €145 million (about $170 million) in cash. The deal will integrate the acquired Lab Products portfolio into Eurobio’s GenDx operations and is intended to expand GenDx’s comprehensive transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions.
-
Taconic Biosciences Acquires TransCure bioServices
January 20, 2026
Biotechnology
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
mdxhealth to Acquire Bio-Techne’s Exosome Diagnostics Business (ExoDx Prostate)
August 5, 2025
Healthcare Services
Bio-Techne Corporation has reached an agreement for mdxhealth SA to acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test and CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to proprietary exosome-based technology for ongoing kit development, and expects the transaction to be completed in the first quarter of fiscal 2026.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Synopsys Acquires Code Dx
June 8, 2021
Cybersecurity
Synopsys, Inc. acquired Code Dx, an application security risk management vendor based in Northport, New York, to extend Synopsys' application security portfolio and provide consolidated vulnerability aggregation, correlation, and prioritization across multiple testing tools. The deal adds Code Dx's R&D team and technology into Synopsys' Software Integrity Group to improve risk reporting and DevSecOps orchestration.
-
Abenex Acquires Cisbio Bioassays from Argos Soditic
June 16, 2016
Biotechnology
French private equity firm Abenex has acquired Cisbio Bioassays from seller Argos Soditic. Abenex will partner with the biotech to support its organic and external growth strategy across pharmaceutical research and in vitro diagnostics; Cisbio has ~210 employees and generates over 85% of revenue outside France.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.